

REPORTS

PROSTAGLANDIN AND DNA SYNTHESIS IN HUMAN SKIN: POSSIBLE RELATIONSHIP TO ULTRAVIOLET LIGHT EFFECTS

WILLIAM H. EAGLSTEIN, M.D., AND GERALD D. WEINSTEIN, M.D.

Department of Dermatology, University of Miami School of Medicine, Miami, Florida

The effect of prostaglandin E₂ (PGE₂) on DNA synthesis in human skin was evaluated. PGE₂ (1 μg) was injected intradermally into normal buttock skin of 15 volunteers followed by tritiated thymidine for autoradiographic quantitation of DNA synthesizing cells. Controls of normal saline, histamine (50 μg), and lower doses of PGE₂ were also injected into 8 of the volunteers.

Forty-eight hours after injection of 1 μg and 0.1 μg PGE₂ there was a 264% and 62% increase, respectively, in the number of DNA synthesizing epidermal cells/high-power field as compared to saline controls. These differences were statistically significant ($p < 0.01$). Histamine (50 μg) produced a statistically significant 36% higher labeling index compared to its saline controls ($p < 0.05$).

Many types of skin injury, including ultraviolet light (UVL) irradiation, produce an increase in the number of DNA synthesizing cells about 48 hr after the stimulus. Our findings suggest that PGE, a putative mediator of UVL-induced inflammation, may be one of the chemical mediators for the UVL-induced increase in DNA synthesizing cells. Histamine may also contribute to the increase in DNA synthesizing cells following UVL-induced inflammation.

The prostaglandins are fatty acids which are found in many tissues and have a wide variety of physiologic actions. Prostaglandins of the E series (PGE) cause long-lasting redness when injected into skin [1]. They are synthesized by human skin [2] and have been implicated as mediators of ultraviolet light (UVL)-induced inflammation. Prostaglandin-like chemicals have been identified in dermal perfusates from UVL-irradiated skin [3] and PGE has been identified in homogenates of UVL-irradiated skin [4]. Drugs such as indomethacin and aspirin, which inhibit the PG synthetase system [5], will delay and decrease UVL-induced inflammation [6].

UVL irradiation of normal skin causes an initial decrease in the number of epidermal DNA synthesizing (S-phase) cells followed by a 3- to 6-fold increase in the number of [³H]thymidine-labeled (S-phase) cells at 48 hr after irradiation compared to unirradiated skin [7].

The relationship between UVL-induced inflam-

mation and UVL-induced changes in DNA synthesis is not understood. If PGE mediates UVL-induced inflammation, does it also mediate UVL-induced changes in DNA synthesis? To study this question, PGE₂ was injected into normal human skin and its effects on DNA synthesis were evaluated by autoradiography and the similarity of these effects to those found following UVL irradiation were compared.

MATERIALS AND METHODS

PGE₂, following confirmation of purity by thin-layer chromatography, was diluted in saline for intradermal injections of 0.05 ml in amounts of 1 μg, 0.1 μg, 0.01 μg, and 0.0001 μg. Intradermal injections of 0.05 ml of saline and histamine (50 μg/0.05 ml saline) were used as controls. Fifteen men and women between 45 and 92 years of age, after signing informed consent forms, participated in the study. The injections were performed with tuberculin syringes and 26-gauge needles on normal-appearing buttock skin. Each injection produced a distinct wheal indicating delivery high in the dermis. The injection test sites were separated from one another by at least 2.5 cm. At the appropriate time after administration of the test agent, [³H]thymidine (sp act 6.0 Ci/mm³, 5 μCi/0.1 ml of saline) was injected into each test site. Four-millimeter punch biopsy specimens were obtained from the test sites 30 to 45 min following the injection of the [³H]thymidine. The specimens were fixed in Bouin's solution and prepared for histologic and autoradiographic analysis as previously described [8].

Autoradiographs were examined for heavily labeled

Manuscript received September 16, 1974; in revised form January 3, 1975; accepted for publication January 17, 1975.

This work was supported by Grants Nos. 3T01 AM 5262, CA 14395, and RO1 AM 14887 from the National Institute of Arthritis, Metabolism, and Digestive Diseases.

Reprint requests to: Dr. W. H. Eaglstein, Department of Dermatology, University of Miami School of Medicine, P. O. Box 520875, Biscayne Annex, Miami, Florida 33152.

cells (more than 10 grains) in the interfollicular epidermis. Between 40 and 50 high-power fields (HPF) (ocular 10 \times , objective 40 \times) of each specimen were examined. Each HPF was 0.25 mm in surface length and contained approximately 50 basal cells along the interfollicular epidermis. The results are expressed as the number of heavily labeled cells per HPF (labeling index, L. I.)

Three subjects each received 5 injections of 1 μ g PGE₂ and 5 injections of saline at different sites. At 0.5, 1.5, 3, 24, and 48 hr after the PGE₂ and saline injections, [³H]thymidine was injected into these test sites followed by biopsies. Two subjects were studied only during the first three time periods. Ten different subjects were injected with saline and 1 μ g PGE₂, followed by [³H]thymidine and biopsy 48 hr later. Eight of these subjects were given additional injections of PGE₂ in lower concentrations (0.1, 0.01, or 0.0001 μ g/0.05 ml) and an injection of histamine solution (50 μ g/0.05 ml) for testing at the 48-hr time period.

RESULTS

Clinically, all injections of PGE₂ produced redness within 2 to 6 min. The area of redness following 1 μ g of PGE₂ was oval, reaching a maximum diameter of 2.5 cm within 15 min and persisting approximately 5 hr. The lower doses of PGE₂ produced a smaller area of redness which resolved sooner than the 1- μ g dose. Red streaks or "tails" extended from the oval PGE₂-induced areas of redness. The histamine injections produced immediate redness and marked whealing. The histamine-induced redness was less intense than the PGE₂-induced redness, extended over a larger area (5 cm diameter), and resolved within 2 hr. The saline injections did not produce redness.

Histologically, there was no apparent difference in either the thickness of the epidermis or the configuration of the rete ridges among the specimens injected with PGE₂, histamine, and saline.

The thymidine labeling indices showed no significant differences between PGE₂-injected and saline-injected sites over the first 24 hr. The labeling indices produced by the saline control injection sites were the same over the first 3 hr, but increased slightly at 24 and 48 hr after injection (Tab. I).

Of major interest was the observation that at 48 hr after injection there was a 264% increase in the number of labeled cells per HPF in the 1 μ g PGE₂

TABLE I. Mean labeling indices* in human skin at various hours following intradermal injection of 1 μ g PGE₂ and saline control

	Hours after injection				
	0.5	1.5	3	24	48
Number of subjects	5	5	5	3	13
Mean L.I.: saline	1.7	1.8	1.7	2.5	3.1
Mean L.I.: PGE ₂ 1 μ g	1.4	2.1	1.7	3.2	8.2

* Labeling index (L.I.) = number of tritiated thymidine labeled epidermal cells/high-power field (50 basal cells).

TABLE II. The effects of intradermal PGE₂, histamine, and saline on labeling indices at 48 hr after injection

Pt. #	Number of labeled cells per high-power field					Hista- mine 50 μ g
	Saline	PGE ₂				
		1 μ g	0.1 μ g	0.01 μ g	0.0001 μ g	
1	4.8	12.1				
2	2.7	20.0				
3	5.1	12.3				
4	2.9	6.4				
5	2.2	8.8				
6	2.1	5.2	5.5			3.5
7	3.1	4.1	3.8	7.7	1.8	3.2
8	4.7	10.7		5.5	4.7	6.8
9	2.9	4.8		4.1	3.4	3.0
10	3.4	7.7		5.5	4.5	2.6
11	2.5	8.5		5.6	1.8	4.9
12	1.8	0.6	6.5	4.0		2.6
13	1.6	5.2	3.0	1.9		3.6
Mean	3.1	8.2	4.7	4.7	3.2	3.8
Standard error	0.32	1.3	0.8	1.1	0.7	0.4

sites as compared to their saline controls. This difference is statistically significant, $p < 0.01$ (matched-pair comparison). The lower dose of 0.01 μ g PGE₂ caused a 62% increase in the labeling index at 48 hr ($p < 0.01$, matched-pair comparison). Histamine (50 μ g) produced a 36% higher labeling index compared to its saline controls ($p < 0.05$, matched-pair comparison) (Tab. II).

DISCUSSION

We have demonstrated that an erythema-producing intradermal injection of PGE₂ into normal skin is associated with an increase in epidermal DNA synthesizing cells at 48 hr following injection. This is the same time at which an increase in S-phase cells occurs in UVL-irradiated skin. The prostaglandin doses used in this study are well within ranges reported in UVL-damaged skin [4]. The lowest doses which increased the number of S-phase cells (0.1 and 0.01 μ g) are below those reported in skin [9, 10].

An increase in human epidermal S-phase cells at 24 to 48 hr can be demonstrated following several different stimuli: UVL irradiation [7], Scotch-tape stripping [11], incisional wounding [12], and friction [13]. A similar increase in the number of S-phase cells also has been noted in certain animal models with specific timed increases following stimuli such as skin friction [14], wounding [15], isoproteranol injections into mice for salivary gland cell proliferation [16], and mouse hepatocellular injury. These observations suggest that cell proliferation in response to certain stimuli requires a finite time period to develop.

One can only speculate at this time on how PGE₂ administration affects the epidermal cell cycle.

Since the labeling index did not decrease but remained relatively normal from 1 to 24 hr following PGE₂ injection (Tab. I), there does not appear to be a block in the movement of cells from G₁ into the S-phase. However, at 48 hr following PGE₂ injection, a "burst" of cells appears in the S phase suggesting either an abrupt shortening of the G₁ period or stimulation of G₁ cells into the S phase as a synchronous group. Theoretically it could also reflect a stimulation of G₀ cells into the S phase at 48 hr, but as yet there is no evidence supporting the existence of G₀ cells in human epidermis.

The failure to find an initial decrease in the number of epidermal DNA synthesizing cells following PGE₂ injection supports the suggestion that the decreased number of S-phase epidermal cells seen within the first few hours after UVL irradiation is due to a direct damaging effect of UVL on epidermal DNA [17].

At the molecular level, the prostaglandins and cyclic nucleotides appear to modulate various cellular functions. In general, prostaglandins of the E series stimulate an increase in the levels of cyclic AMP (cAMP); however, the relationship between cAMP and DNA synthesis is variable. Increased DNA synthesis is associated with increased cAMP levels in rat salivary gland following isoproteranol injection [18], whereas increased DNA synthesis is associated with decreased cAMP levels in fibroblastic cell cultures stimulated with GMP [19]. Cultured fibroblasts are associated with varying cAMP levels throughout the cell cycle but cGMP increases are found in the early G₁ phase [20]. A recent review of the literature [21] with special emphasis on model systems employing thymocytes and regenerating liver cells concludes that increased DNA synthesis follows an increase in cAMP levels.

When normal and psoriatic epidermal cells were studied in vitro, the addition of dibutyryl cAMP in high concentrations inhibited mitoses [22,23]. However, in the rapidly proliferating psoriatic epidermis, both increased [24,25] and decreased [26] levels of cAMP have been reported, leading to conflicting interpretations of the relationship between cAMP and mitotic behavior. Prostaglandins of the E series are reported in in vitro epidermal cell systems to increase cAMP levels [27,28]. Since cAMP concentrations were not measured in the present in vivo studies, we are unable to clarify the relationship between our data and the cAMP effects of DNA synthesizing cells.

As PGE₂ plays a role in the inflammatory response to UVL irradiation, our present findings suggest that PGE₂ may be one of the mediators of the increased number of S-phase cells seen following UVL irradiation. Histamine has also been reported in dermal perfusates of UVL-irradiated skin [29]. Since an increased number of S-phase cells was found 48 hr following histamine injection, it is possible that histamine also contributes to the increased number of DNA synthesizing cells following UVL irradiation. However, the dramatic

whealing from our histamine injection of 50 µg is not seen in the skin following UVL irradiation. The demonstration that defined chemical molecules are capable of stimulating proliferative cell activity in the skin may be significant for future biochemical and cytokinetic studies.

REFERENCES

1. Solomon LM, Juhlin L, Kirschenbaum MB: Prostaglandins on cutaneous vasculature. *J Invest Dermatol* 51:280-282, 1968
2. Ziboh VA, McElligott T, Hsia SL: Prostaglandin E₂ biosynthesis in human skin: subcellular localization and inhibition by unsaturated fatty acids and anti-inflammatory agents. *Adv Biosci (Suppl)* 9:71, 1972
3. Greaves MW, Søndergaard J: Pharmacologic agents released in ultraviolet inflammation studied by continuous skin perfusion. *J Invest Dermatol* 54:365-367, 1970
4. Mathur GP, Gandhi VM: Prostaglandin in human and albino rat skin. *J Invest Dermatol* 58:291-295, 1972
5. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. *Nature [New Biol]* 231:232-235, 1971
6. Snyder DS, Eaglstein WH: Intradermal anti-prostaglandin agents and sunburn. *J Invest Dermatol* 62:47-50, 1974
7. Epstein WL, Fukuyama K, Epstein JH: Ultraviolet light, DNA repair and skin carcinogenesis in man. *Fed Proc* 30:1766-1771, 1971
8. Weinstein GD, Van Scott EJ: Autoradiographic analysis of turnover times of normal and psoriatic epidermis. *J Invest Dermatol* 45:257-262, 1965
9. Aso K, Orenberg EK, Rabinowitz N, Farber EM: The reduced levels of prostaglandins and the effect of prostaglandin stimulation on cAMP accumulation in psoriatic epidermis (abstr). *J Invest Dermatol* 62:545, 1974
10. Jonsson CE, Ånggård E: Biosynthesis and metabolism of prostaglandin E₂ in human skin. *Scand J Clin Lab Invest* 2:289-296, 1972
11. Rovee DT, Kurowsky CA, Labun J: Local wound environment and epidermal healing. *Arch Dermatol* 106:330-334, 1972
12. Epstein WL, Sullivan DJ: Epidermal mitotic activity in wounded human skin, *Advances in Biology of Skin*, vol. 5. Edited by W Montagna, RE Billingham. New York, Pergamon, 1964, pp 68-75
13. Epstein WL, Fukuyama K, Cortese TA: Autoradiographic study of friction blisters. *Arch Dermatol* 99:94-106, 1969
14. Mackenzie IC: The effects of frictional stimulation on mouse ear epidermis. I. Cell proliferation. *J Invest Dermatol* 62:80-85, 1974
15. Giacometti L: The healing of skin wounds in primates. *J Invest Dermatol* 48:133-137, 1967
16. Baserga R: Induction of DNA synthesis by a purified chemical compound. *Fed Proc* 29:1443, 1970
17. Kramer DM, Pathak MA, Kornhauser A, Wischemann A: Effect of ultraviolet irradiation on biosynthesis of DNA in guinea-pig skin in vivo. *J Invest Dermatol* 62:388-393, 1974
18. Durham JP, Baserga R, Butcher FR: Lack of correlation between catecholamine analog effects on cyclic AMP levels and A denylate cyclase activity and the stimulation of DNA synthesis in mouse parotid gland. *Cold Spring Harbor Symp Quant Biol* 1:595-607, 1974
19. Seifert WE, Rudland PS: Possible involvement of cyclic GMP in growth control of cultured mouse cells. *Nature (Lond)* 248:138-140, 1974
20. Rudland PS, Gospodarowicz D, Seifert W: Activation of guanyl cyclase and intracellular cyclic GMP by fibroblast growth factor. *Nature (Lond)* 250:771-773, 1974

21. MacManus JP, Whitfield JF: Cyclic AMP, prostaglandins and the control of cell proliferation. *Prostaglandins* 6:475-487, 1974
22. Harper RA, Flaxman BA, Chopra DP: Mitotic response of normal and psoriatic keratinocytes in vitro to compounds known to affect intracellular cyclic AMP. *J Invest Dermatol* 62:384-387, 1974
23. Voorhees JJ, Duell EA, Kelsey WH: Dibutyryl cyclic AMP inhibition of epidermal cell division. *Arch Dermatol* 105:384-386, 1972
24. Härkönen M, Hopsu-Havu VK, Raij K: Cyclic adenosine monophosphate, adenylyl cyclase and cyclic nucleotide phosphodiesterase in psoriatic epidermis. *Acta Derm Venereol (Stockh)* 54:13-18, 1974
25. Yoshikawa K, Adachi K, Halprin KM, Levine V: Is the cyclic AMP level in psoriasis low? *Br J Dermatol* (in press)
26. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell ER: Decreased cyclic AMP in the epidermis of lesions of psoriasis. *Arch Dermatol* 105:695, 1972
27. Adachi K, Yoshikawa K, Halprin KM, Levine V: Prostaglandins and cyclic AMP in epidermis. *Br J Dermatol* (in press)
28. Mei MM, Hsia SL, Halprin KM: Further studies on adenylyl cyclase in psoriasis. *Br J Dermatol* (in press)
29. Sondergaard J, Greaves MW: Pharmacological studies in inflammation due to exposure to ultraviolet radiation. *J Pathol* 101:93-97, 1970